Wedbush Predicts Arcus Biosciences’ Q2 Earnings (NYSE:RCUS)

Arcus Biosciences, Inc. (NYSE:RCUS) – Research analysts at Wedbush cut their Q2 2025 earnings per share (EPS) estimates for shares of Arcus Biosciences in a report released on Wednesday, May 7th. Wedbush analyst R. Driscoll now forecasts that the company will earn ($1.11) per share for the quarter, down from their previous estimate of ($1.01). Wedbush currently has a “Outperform” rating and a $33.00 target price on the stock. The consensus estimate for Arcus Biosciences’ current full-year earnings is ($3.15) per share. Wedbush also issued estimates for Arcus Biosciences’ Q3 2025 earnings at ($1.13) EPS, Q4 2025 earnings at ($1.15) EPS, FY2025 earnings at ($4.53) EPS, FY2026 earnings at ($4.32) EPS, FY2027 earnings at ($3.60) EPS, FY2028 earnings at ($0.52) EPS and FY2029 earnings at $3.37 EPS.

RCUS has been the subject of several other research reports. Morgan Stanley lowered their price objective on Arcus Biosciences from $24.00 to $22.00 and set an “overweight” rating for the company in a research report on Friday. HC Wainwright raised Arcus Biosciences from a “neutral” rating to a “buy” rating and upped their price target for the company from $18.00 to $24.00 in a research report on Wednesday, February 26th. Barclays dropped their price objective on Arcus Biosciences from $29.00 to $14.00 and set an “overweight” rating for the company in a report on Wednesday, April 23rd. Bank of America decreased their target price on Arcus Biosciences from $22.00 to $17.00 and set a “neutral” rating for the company in a report on Wednesday, February 19th. Finally, Wells Fargo & Company cut their price target on shares of Arcus Biosciences from $29.00 to $26.00 and set an “overweight” rating on the stock in a report on Wednesday. Two investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Arcus Biosciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $25.67.

Arcus Biosciences Stock Performance

NYSE RCUS opened at $8.28 on Friday. The firm has a market cap of $876.73 million, a price-to-earnings ratio of -2.63 and a beta of 0.88. Arcus Biosciences has a 12-month low of $6.50 and a 12-month high of $18.98. The company has a 50-day simple moving average of $8.40 and a two-hundred day simple moving average of $12.43. The company has a quick ratio of 5.24, a current ratio of 5.24 and a debt-to-equity ratio of 0.08.

Arcus Biosciences (NYSE:RCUS) last announced its quarterly earnings data on Tuesday, May 6th. The company reported ($1.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.12). Arcus Biosciences had a negative return on equity of 45.59% and a negative net margin of 102.66%. The business had revenue of $28.00 million during the quarter, compared to the consensus estimate of $38.61 million. During the same quarter in the previous year, the firm posted ($0.05) earnings per share. The company’s revenue was down 80.7% compared to the same quarter last year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of RCUS. Barclays PLC increased its position in shares of Arcus Biosciences by 49.0% during the third quarter. Barclays PLC now owns 118,693 shares of the company’s stock valued at $1,816,000 after acquiring an additional 39,015 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in shares of Arcus Biosciences by 2.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 43,685 shares of the company’s stock worth $668,000 after purchasing an additional 1,117 shares in the last quarter. Nordea Investment Management AB raised its stake in shares of Arcus Biosciences by 2.5% in the fourth quarter. Nordea Investment Management AB now owns 218,930 shares of the company’s stock worth $3,245,000 after purchasing an additional 5,246 shares during the last quarter. R Squared Ltd bought a new position in shares of Arcus Biosciences during the fourth quarter valued at $26,000. Finally, Principal Financial Group Inc. boosted its position in shares of Arcus Biosciences by 3.1% during the fourth quarter. Principal Financial Group Inc. now owns 263,517 shares of the company’s stock valued at $3,924,000 after buying an additional 7,906 shares during the last quarter. 92.89% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Arcus Biosciences

In related news, CEO Terry J. Rosen acquired 19,800 shares of the stock in a transaction on Thursday, February 27th. The stock was acquired at an average price of $10.18 per share, for a total transaction of $201,564.00. Following the completion of the purchase, the chief executive officer now owns 2,554,160 shares of the company’s stock, valued at $26,001,348.80. This represents a 0.78 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Yasunori Kaneko bought 20,000 shares of the company’s stock in a transaction on Thursday, February 27th. The stock was bought at an average cost of $10.06 per share, for a total transaction of $201,200.00. Following the completion of the acquisition, the director now directly owns 28,400 shares of the company’s stock, valued at approximately $285,704. This represents a 238.10 % increase in their position. The disclosure for this purchase can be found here. 12.30% of the stock is currently owned by corporate insiders.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.